Literature DB >> 8949584

The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy.

J M Weiss1, P H Morgan, M W Lutz, T P Kenakin.   

Abstract

Early work in pharmacology characterized the interaction of receptors and ligands in terms of two parameters, affinity and efficacy, an approach we term the bipartite view. A precise formulation of efficacy only exists for very simple pharmacological models. Here we extend the notion of efficacy to models that incorporate receptor activation and G-protein coupling. Using the cubic ternary complex model, we show that efficacy is not purely a property of the ligand-receptor interaction; it also depends upon the distributional details of the receptor species in the native receptor ensemble. This suggests a distinction between what we call potential efficacy (a vector) and realized efficacy (a scalar). To each receptor species in the native receptor ensemble we assign a part-worth utility; taken together these utilities comprise the potential efficacy vector. Realized efficacy is the expectation of these part-worth utilities with respect to the frequency distribution of receptor species in the native receptor ensemble. In the parlance of statistical decision theory, the binding of a ligand to a receptor ensemble is a random prospect and realized efficacy is the utility of this prospect. We explore the implications that our definition of efficacy has for understanding agonism and in assessing the legitimacy of the bipartite view in pharmacology.

Mesh:

Substances:

Year:  1996        PMID: 8949584     DOI: 10.1006/jtbi.1996.0139

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  63 in total

1.  Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay.

Authors:  C Parnot; S Bardin; S Miserey-Lenkei; D Guedin; P Corvol; E Clauser
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

2.  Protean agonism at histamine H3 receptors in vitro and in vivo.

Authors:  Florence Gbahou; Agnès Rouleau; Séverine Morisset; Régis Parmentier; Sylvain Crochet; Jian-Sheng Lin; Xavier Ligneau; Joël Tardivel-Lacombe; Holger Stark; Walter Schunack; C Robin Ganellin; Jean-Charles Schwartz; Jean-Michel Arrang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

3.  How to impose microscopic reversibility in complex reaction mechanisms.

Authors:  David Colquhoun; Kathryn A Dowsland; Marco Beato; Andrew J R Plested
Journal:  Biophys J       Date:  2004-06       Impact factor: 4.033

Review 4.  Biased signalling and allosteric machines: new vistas and challenges for drug discovery.

Authors:  Terry P Kenakin
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 5.  The significance of G protein-coupled receptor crystallography for drug discovery.

Authors:  John A Salon; David T Lodowski; Krzysztof Palczewski
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 6.  Ensemble of G protein-coupled receptor active states.

Authors:  P S-H Park
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 7.  G protein coupled receptor structure and activation.

Authors:  Brian K Kobilka
Journal:  Biochim Biophys Acta       Date:  2006-11-15

8.  Relaxation gating of the acetylcholine-activated inward rectifier K+ current is mediated by intrinsic voltage sensitivity of the muscarinic receptor.

Authors:  Eloy G Moreno-Galindo; José A Sánchez-Chapula; Frank B Sachse; J Alberto Rodríguez-Paredes; Martin Tristani-Firouzi; Ricardo A Navarro-Polanco
Journal:  J Physiol       Date:  2011-01-31       Impact factor: 5.182

Review 9.  The serotonin 5-HT7 receptors: two decades of research.

Authors:  Evelien Gellynck; Karen Heyninck; Kjetil W Andressen; Guy Haegeman; Finn Olav Levy; Peter Vanhoenacker; Kathleen Van Craenenbroeck
Journal:  Exp Brain Res       Date:  2013-09-17       Impact factor: 1.972

Review 10.  Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications.

Authors:  N T Burford; J R Traynor; A Alt
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.